<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05622994</url>
  </required_header>
  <id_info>
    <org_study_id>FHNP-CT003</org_study_id>
    <nct_id>NCT05622994</nct_id>
  </id_info>
  <brief_title>Effects of CB1 Antagonist/Reverse Agonist Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury</brief_title>
  <acronym>RIMOFATSCI-2</acronym>
  <official_title>Efectos de un Antagonista/Agonista Inverso Del Receptor CB1 (Rimonabant) Sobre la Capacidad Para la deambulación en Lesionados Medulares Incompletos</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Nacional de Parapléjicos de Toledo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Nacional de Parapléjicos de Toledo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a placebo controlled study comparing Rimonabant 5 mg per day for 90 days with placebo&#xD;
      for the same period. Objective is to improve walking abilities of spinal cord injury&#xD;
      individuals (incomplete lesions) and demonstrate that it is a safe treatment in spinal cord&#xD;
      injury population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a placebo controlled study comparing Rimonabant 5 mg per day for 90 days with placebo&#xD;
      for the same period.&#xD;
&#xD;
      Main goal are to test safety and efficacy (impairment of walking abilities teste with the 6&#xD;
      min walking test) of Rimonabant in a specific population (incomplete spinal cord injury).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2022</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Placebo controlled parallel design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (Safety)</measure>
    <time_frame>120 days</time_frame>
    <description>Number of AE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemical and urine analysis (safety)</measure>
    <time_frame>120 days</time_frame>
    <description>Number of participants with clinically significant abnormal laboratory tests results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG (safety)</measure>
    <time_frame>120 days</time_frame>
    <description>Number of participants with clinically significant abnormal ECG readings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HAD) (safety</measure>
    <time_frame>120 days</time_frame>
    <description>Range 0-21(higher values more severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Ashworth Scale (safety)</measure>
    <time_frame>90 days</time_frame>
    <description>Range 0-4 (higher values more severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Penn Scale (safety)</measure>
    <time_frame>90 days</time_frame>
    <description>Range 0-4 (higher values more severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain numeric rating scale (safety)</measure>
    <time_frame>90 days</time_frame>
    <description>Range 0-10 (higher values more severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Questionnaire of falls (safety)</measure>
    <time_frame>120 days</time_frame>
    <description>Number of falls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 min walking test (efficacy)</measure>
    <time_frame>90 days</time_frame>
    <description>6 min walking test (meters and number of stops are reported)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>10 m test (efficacy)</measure>
    <time_frame>90 days</time_frame>
    <description>Time to walk 10 m (no stops are allowed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg Scale (efficacy)</measure>
    <time_frame>90 days</time_frame>
    <description>Borg Scale punctuation after 6 min waking test. Range 0-10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor Score (efficacy)</measure>
    <time_frame>90 days</time_frame>
    <description>Motor Score (ISNCSCI). Range 0-20 (higher values less severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Severity Scale (FSS) (Efficacy)</measure>
    <time_frame>90 days</time_frame>
    <description>FSS puntuación. Range 0-7 (higher values more severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global impression of changes (PGIC) (efficacy)</measure>
    <time_frame>90 days</time_frame>
    <description>PGIG score. Range 1-7 (higher values indicate worsening)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Quality of Life -5 Dimensions (EQ-5D) (efficacy)</measure>
    <time_frame>90 days</time_frame>
    <description>EQ-5D questionnaires have 5 dimensions: &quot;Mobility&quot;, &quot;Human Autonomy,&quot; &quot;Current Activities&quot;, &quot;Pain / Discomfort&quot;, &quot;Anxiety / Depression&quot; and all dimensions are described by 3 problem levels corresponding to patient response choices (higher values worst). A quality-of-life score is obtained according to the answers to the questionnaires (algorithm to calculate the score in euroqol.org). The maximum score is 1 that indicates excellent quality of life (range for Spanish version 0.5-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health state visual analogically scale (efficacy)</measure>
    <time_frame>90 days</time_frame>
    <description>Range 0-100 mm (higher values indicate higher health state )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spinal Cord Independence Measures, SCIM (efficacy)</measure>
    <time_frame>90 days</time_frame>
    <description>Range 0-100 (higher values indicate higher independence )</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Spinal Cord Injuries</condition>
  <arm_group>
    <arm_group_label>Rimonabant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rimonabant 5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimonabant</intervention_name>
    <description>Rimonabant 5mg per day is administered for 90 days. The comparator is placebo for the same duration.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Rimonabant</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 yo and &lt;75yo&#xD;
&#xD;
          -  Non progressive spinal cord injury&#xD;
&#xD;
          -  Incomplete lesion (AIS C or D)&#xD;
&#xD;
          -  Neurological level between C4 and L1&#xD;
&#xD;
          -  Chronic stage (&gt;1 year since injury)&#xD;
&#xD;
          -  Preserved walking ability for at least 5 m (aid allowed)&#xD;
&#xD;
          -  Capability to provide informed consent&#xD;
&#xD;
          -  For fertile women, possibility to use anti conceptive methods&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 yo or &gt;75&#xD;
&#xD;
          -  AIS A, B or E&#xD;
&#xD;
          -  Neurological level above C4 or below L1&#xD;
&#xD;
          -  Subacute stage (&lt;1 year since injury)&#xD;
&#xD;
          -  Preserved walking ability for less than 5 m (aid allowed)&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  For fertile women, impossibility to use anti conceptive methods&#xD;
&#xD;
          -  anticoagulant treatment&#xD;
&#xD;
          -  Hypothyroidism&#xD;
&#xD;
          -  Severe bone, kidney or liver disfunction&#xD;
&#xD;
          -  Impossibility to reach the hospital&#xD;
&#xD;
          -  Impossibility to rovide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Oliviero, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Nacional de Parapléjicos</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Oliviero, MD, PhD</last_name>
    <phone>+34925247700</phone>
    <phone_ext>47120</phone_ext>
    <email>antonioo@sescam.jccm.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Nacional de Paraplejicos</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Nacional de Parapléjicos de Toledo</investigator_affiliation>
    <investigator_full_name>Antonio Oliviero</investigator_full_name>
    <investigator_title>Antonio Oliviero</investigator_title>
  </responsible_party>
  <keyword>walking abilities</keyword>
  <keyword>Rimonabant</keyword>
  <keyword>Endurance</keyword>
  <keyword>Incomplete SCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rimonabant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

